High-effect synergy from dual HDAC6 and YAP–TEAD inhibition in ovarian clear cell carcinoma
Authors:
Open Access
- 30 January 2026
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 26 (1)
Abstract
Ovarian clear cell carcinoma (OCCC) is an aggressive epithelial subtype characterized by intrinsic chemoresistance and limited targeted therapies. TranscriKeywords
Funding Information
- Kanzawa Medical Research Foundation
This publication has 27 references indexed in Scilit:
- YAP‐TEAD inhibition is associated with upregulation of an androgen receptor mediated transcription program providing therapeutic escapeFEBS Open Bio, 2024
- Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancersNature Cancer, 2024
- Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomesGynecologic Oncology, 2021
- Expression of the chrXq27.3 miRNA cluster in recurrent ovarian clear cell carcinoma and its impact on cisplatin resistanceOncogene, 2021
- YAP/TAZ: Drivers of Tumor Growth, Metastasis, and Resistance to TherapyBioEssays, 2020
- Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growthOncogene, 2015
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapiesNature Genetics, 2015
- Connective Tissue Growth Factor is a Target of Notch Signaling in Cells of the Osteoblastic LineageBone, 2014
- Verteporfin Photodynamic Therapy Cohort Study: Report 1: Effectiveness and Factors Influencing OutcomesOphthalmology, 2009
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001